Sun Pharma to raise stake in US-based Pharmazz to 22.7%

Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%

Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Borealis advancing sustainability medical devices with the Bornewables

The Protect VL project was born out of a vision to reduce the environmental footprint of medical devices

GPT Healthcare commissions new greenfield quaternary care hospital in Raipur

ekincare raises investment from MSD IDEA Studio Asia Pacific

ekincare has raised a total funding of $22M since 2015 till date

DHL Express and Sai Life Sciences sign GoGreen Plus partnership to make pharma deliveries more sustainable

The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF

Carbogen Amcis Shanghai site receives drug manufacturing license from Chinese NMPA

AstraZeneca, Daiichi Sankyo announce Enhertu plus pertuzumab demonstrated clinically meaningful improvement as 1st-line therapy for patients with metastatic breast cancer

DESTINY-Breast09 Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current 1st-line standard of care